image credit: Unsplash

Beacon lights up with $170m for retinal disease gene therapy

July 3, 2024

The Series B – led by Forbion and joined by other investors, including Syncona, Oxford Science Enterprises, and Oxford University Innovation – takes the total raised by Beacon since its formation last year to $290 million, making it a rising star on the UK life sciences scene.

It is focusing on retinal diseases, with its most advanced programme AGTC-501 for X-linked retinitis pigmentosa (XLRP), which is in the phase 2/3 VISTA trial.

Read More on Pharmaphorum